Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 6/20 | 0.81 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.69 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.69 |
| ▸ | SOD1 | P00441 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24177920 | 1.00 | POLA1 (0.81) | POLA1NR1H2NR1H3SOD1CYP3A4 | |
| SCHEMBL19770990 | 1.00 | POLA1 (0.81) | POLA1NR1H2NR1H3SOD1CYP3A4 | |
| SCHEMBL7767289 | 1.00 | POLA1 (0.81) | POLA1NR1H2NR1H3SOD1CYP3A4 | |
| SCHEMBL12292033 | 1.00 | POLA1 (0.81) | POLA1NR1H2NR1H3SOD1CYP3A4 | |
| SCHEMBL25873377 | 0.91 | POLA1 (0.68) | POLA1NR1H2NR1H3SOD1CYP3A4 | |
| SCHEMBL19785805 | 0.90 | NR1H2 (0.69) | POLA1NR1H2NR1H3SOD1CYP3A4 | |
| SCHEMBL280198 | 0.89 | POLA1 (1.00) | POLA1NR1H2NR1H3CYP3A4CYP2C9 | |
| SCHEMBL12872352 | 0.89 | POLA1 (1.00) | POLA1NR1H2NR1H3CYP3A4CYP2C9 | |
| SCHEMBL5510769 | 0.89 | POLA1 (1.00) | POLA1NR1H2NR1H3CYP3A4CYP2C9 | |
| SCHEMBL29295275 | 0.87 | POLA1 (0.62) | POLA1NR1H2NR1H3SOD1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180015051-A1 | MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR THE TREATMENT OF DIABETIC PATHOLOGIES | BUCK INST RES AGING (US) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180015051-A1 | MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR THE TREATMENT OF DIABETIC PATHOLOGIES | TRPA1, TRPV1, TRPM2 | POLA1 3859/4885NR1H2 841/4885NR1H3 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.